Key result
Endothelin-1 and vascular endothelial growth factor stimulate intimal hyperplasia, suggesting that ET-1 receptor antagonists may play a prominent role in the prophylaxis of restenosis.
Why the study?
Do ET-1 receptor antagonists prevent restenosis in patients with arterial vascular disease undergoing angioplasty and stent implantation?
Do ET-1 receptor antagonists prevent restenosis in patients with arterial vascular disease undergoing angioplasty and stent implantation?
ET-1 receptor antagonists represent a potential therapeutic strategy for preventing restenosis following angioplasty and stent implantation.
ET-1 antagonists merit testing to prevent restenosis; leaves open clinical efficacy pending randomized trials.
Restenosis is a common and serious complication following angioplasty and stent implantation in patients with arterial vascular disease. Restenosis is a form of intimal hyperplasia. Endothelin-1 (ET-1) and vascular endothelial growth factor (VEGF) stimulate intimal hyperplasia and may play a role in restenosis. ET-1 and VEGF may act in concert in promoting restenosis following mechanical injury to the vessel wall in angioplasty and stent implantation. An understanding of their mechanism of action may lead to more effective methods for preventing restenosis. ET-1 receptor antagonists may play a prominent role in prophylaxis.
No takes yet. Share an insight, caveat, or question.
Angerio et al. (2001) conducted a review in Restenosis. ET-1 receptor antagonists was evaluated. Endothelin-1 and vascular endothelial growth factor stimulate intimal hyperplasia, suggesting that ET-1 receptor antagonists may play a prominent role in the prophylaxis of restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: